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Thus, the three major goals of future biomarker studies,
as discussed in our review, should be the following: (1) to
differentiate types of AKI at the time of diagnosis (acute
tubular necrosis vs. prerenal vs. other); (2) to predict or
diagnose AKI earlier than the ‘delayed’ clinical diagnosis
via creatinine; (3) to predict hard outcomes (need for
dialysis, length of stay, death) at the time of injury.3
In the absence of associations between biomarkers and
these hard end points, the availability of another
biomarker that ‘mimics’ creatinine will not be beneficial
in advancing the field of AKI. We would encourage
Ferrannini et al. to perform the analyses we have
mentioned in order to determine how cystatin C performs
for predicting these types of end points.
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To the Editor: The article by Davenport et al.1 suggests that
improved blood pressure control increases intradialytic
hypotension. It is unlikely that the reported higher incidence
of hypotension is caused by trying to achieve the Renal
Association targets alone.
In a study of 991 dialysis treatments in 111 patients over a
3-week period, we documented predialysis blood pressures of
136.9±23.4/67.8±14.0 mm Hg and postdialysis blood
pressures of 133.0±24.0/65.8±12.5 mm Hg. The Renal
Association targets were achieved by 56.8% of patients
predialysis, 44.1% postdialysis, and 37.8% achieved both
targets. Intradialytic hypotension occurred in 2.4% of all
treatments. No significant differences were demonstrated in
the blood pressure, interdialytic weight gains or prescribed
medication of those who experienced hypotension and those
who did not.
Two critical factors implemented in our unit may
contribute to these findings. We recognize that short dialysis
times make ultrafiltration more difficult to tolerate and
increase the potential for hypotension. Longer treatment
times are utilized whenever possible with the modal dialysis
time being 4.5 h. Our center utilizes postdilution hemodiafil-
tration as standard. There is increasing evidence that the use
of hemodiafiltration is associated with improvements in
blood pressure control, incidence of intradialytic hypotension
and a reduction in mortality.2–4
Predialysis hypertension does not obviate hypotension
episodes5 and not having targets for blood pressure control
will not necessarily reduce the frequency of hypotension
episodes. When improved control of blood pressure is
desired, modifications to the dialysis treatment itself should
be considered as part of the management strategy.
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High blood pressure is a major health issue in all regions of
the world,1 and myocardial infarction and stroke are the
commonest causes of death and disability worldwide.2
However, although there is a strong relationship between
blood pressure and the risk of cardio- and cerebrovascular
disease in the general population,1,2 this relationship is less
clear for hemodialysis patients, despite the increased
incidence of hypertension in this patient group. Assuming
a normal distribution, then the 95% confidence limits for
pre-dialysis blood pressure recordings were 183/95–91/
39 mm Hg, and 181/91–85/41 mm Hg post-dialysis record-
ings for the patients dialysing in Kilmarnock, and as such
only just over one-third of patients achieved the current
KDOQI blood pressure targets. Thus even in a single unit,
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using hemodiafiltration rather than standard hemodialysis
and dialysing patients for a modal dialysis session time
of 4.5 h, only a minority of patients were able to achieve
the KDOQI and previous UK Renal Association blood
pressure targets,3 in keeping with our multicenter study.4
The UK Renal Association, recently revised its guidelines
and withdrew specific targets for pre- and post-dialysis
blood pressure, on the basis of a lack of evidence-based
data.5
However this does not necessarily imply that blood
pressure control is not important for hemodialysis
patients. It may be that, compared to the general
population, the etiology of hypertension may be more
complex, although sodium and volume overload play an
important role in determining blood pressure control.6 In
addition, although pre- and post-hemodialysis blood
pressure recordings are relatively simple to perform in
clinical practice, they may not accurately reflect inter-
dialytic blood pressure control.
Intradialytic hypotension remains a major side effect of
standard outpatient hemodialysis,7 and is, in part, related to
interdialytic weight gain and increased ultrafiltration
requirement.8 One potential side effect of strict pre- and
post-blood pressure targets could be an increased incidence
of symptomatic intradialytic hypotension. Intradialytic
hypotension has been shown to be associated with both
myocardial and cerebral ischemia,9 and in particular
repetitive myocardial stunning could exacerbate myocardial
fibrosis and so potentially predispose to cardiac arrhyth-
mias. Thus, although blood pressure control is a vital part in
the management of the hemodialysis patient, more study is
required to determine which blood pressure measurements
should be used for setting any future clinical target.
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darusentan for prevention of
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To the Editor: To the best of our knowledge, human studies
and meta-analyses on low-protein diets as a measure for the
prevention of progression of renal disease have never
differentiated between sources of protein.1,2 We therefore
read with great interest the report by Phisitkul et al.,3 in
which it is shown that a diet in which protein is derived from
casein is associated with a more rapid decline in glomerular
filtration rate in remnant kidneys in rats than a diet in which
protein is derived from soy. Large variation in effect of low-
protein diets on progression of renal disease between
different human studies may therefore be the consequence
of variation in the prescription of the preferred source of
protein in a low-protein diet rather than the consequence of
publication bias favoring low-protein diets.1 In our opinion,
the study by Phisitkul et al. challenges the currently held view
that the benefit of a low-protein diet in slowing down
progression in human renal disease is negligible.4 New studies
and meta-analyses should be performed in which sources of
protein and potentially individual amino acids are taken into
account before it is decided whether the effect is negligible for
all low-protein diets.
Phisitkul et al. performed additional experiments and
analyses from which they conclude that the casein-induced
renal injury is mediated by metabolic acidosis through
endothelin A receptors. Their conclusion that metabolic
acidosis is important is substantiated by experiments in
which they show that rats on casein diet have metabolic
acidosis and that decline in glomerular filtration rate can be
prevented by alkalinization with either sodium bicarbonate
(if concomitant blood pressure elevation by the associated
increase in sodium intake was treated) or CaHCO3. The
authors also performed experiments in which they show that
treatment with darusentan can prevent the decline in
glomerular filtration rate occurring in rats on casein diet.
As far as we can oversee, however, the authors did not
perform experiments reported in the paper that substantiate
their overall conclusion that casein-induced renal injury is
mediated by metabolic acidosis through endothelin A
receptors. In the experiments they performed, neither daily
net acid excretion, NH4
þ excretion, nor total acid excretion in
urine was affected by darusentan treatment. Systemic
metabolic acidosis in rats on casein diet was also not affected
by treatment with darusentan. Thus, treatment with
darusentan seems to block the deleterious effect of casein
diet on renal injury independent of its effect on metabolic
acidosis rather than dependent on it. It is important that this
issue is clarified, because acknowledgment of independent
pathways holds the prospect of identification of intriguing
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